Endometrial cancer is a malignancy arising from the endometrium, the inner lining of the uterus. It is one of the most common gynecologic cancers in developed countries and is often diagnosed after menopause. Early-stage detection is associated with favorable outcomes.
In Australia, 19 women are diagnosed daily with gynaecological cancer, and experts say late detection is the primary issue. Ovarian cancer is often caught at advanced stages, while endometrial cancer deaths are rising. Personal stories underscore the need for early symptom awareness.
Sensei Biotherapeutics has changed its name to Faeth Therapeutics following its February 2026 acquisition of the biotechnology company. The name change accompanies a $200 million private placement financing to advance PIKTOR, an investigational all-oral multi-node inhibitor targeting the PI3K/AKT/mTOR pathway in endometrial and breast cancer. Topline Phase 2 data in endometrial cancer is anticipated in the second half of 2026.
GLP-1 receptor agonists combined with progestin therapy significantly reduce endometrial cancer risk in women with uterine hyperplasia, according to a JAMA Network Open study. A separate meta-analysis finds patients regain 60% of weight lost one year after stopping GLP-1 RAs, with weight regain plateauing at 75.3% of treatment loss.
Tempus has launched "Preview," an AI-powered tool that provides early cancer insights within one day of sample receipt to inform treatment planning. The tool focuses on high-impact biomarkers including MSI-H, EGFR mutations, and FGFR fusions across several cancer types. The launch aligns with expert emphasis on the critical role of early biomarker testing in personalizing therapy for EGFR-mutated NSCLC.
A phase II trial of TAK-007 CAR-NK therapy in R/R B-cell NHL showed a 60.9% overall response rate. Preclinical CAR-NKT therapy eliminated endometrial tumors in models. Optimized costimulatory domains (2B4-DAP12) boosted CAR-NK tumor killing.
Acrivon Therapeutics said its wholly owned laboratory in Watertown received Massachusetts CLIA certification with a full license to conduct patient testing and develop companion diagnostics. The company said the lab is expected to be fully operational in the first half of 2026 and will support targeted therapeutics development.
MSD said sacituzumab tirumotecan improved overall survival and progression-free survival in the Phase III TroFuse-005 trial in endometrial cancer. The study also met its objective response rate endpoint.
Sensei Biotherapeutics dosed the first patient in a Phase 1b/2 trial of PIKTOR (sapanisertib + serabelisib) in HR+/HER2- advanced breast cancer. The multi-node PI3K/AKT/mTOR inhibitor previously showed a 47% overall response rate in a Phase 1b trial.
New research reveals GLP-1 receptor agonists reduce substance use disorders by 14%, lower Parkinson's disease risk after 5-10 years of use, and cut endometrial cancer risk by 66% when combined with progestin therapy.
New research shows cancer survivors who exercise reduce their risk of cancer-related death, while expert panel recommends exercise as essential for older cancer patients during and after treatment.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07612891 |
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor |
RECRUITING | PHASE1/PHASE2 |
| NCT07610798 |
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07605247 |
Tirzepatide in the Treatment of Endometrial Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07595224 |
Postoperative Hypofractionated Whole Pelvic Radiotherapy in Cervical and Endometrial Cancer |
RECRUITING | NA |
| NCT07594327 |
Quality of Life and Sexuality After Pelvic Exenteration for Gynecologic Cancer |
ENROLLING_BY_INVITATION | |
| NCT07584161 |
MH-ART vs CF-IMRT in Postoperative Cervical/Endometrial Cancer |
NOT_YET_RECRUITING | NA |
| NCT07583329 |
Comparison of Sentinel Lymph Node Applications in Endometrial Cancer Cases Performed With Vaginal Natural Orifice Transluminal Endoscopic Surgery (V-NOTES) and Conventional Laparoscopy |
NOT_YET_RECRUITING | |
| NCT07581288 |
Measurement of Urinary Hormones in Patients With Abnormal Uterine Bleeding to Study Uterine Cancer Progression |
NOT_YET_RECRUITING | |
| NCT07578649 |
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer |
NOT_YET_RECRUITING | PHASE3 |
| NCT07557225 |
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors |
RECRUITING | NA |
